Among these, TIMP-2 and IGFBP7 are the only FDA-approved AKI biomarkers, targeting G1 cell cycle arrest of tubular epithelial cells and their consequent release at the urinary level following noxious stimuli in several clinical conditions [105,106,107]. The gene discussed is IGFBP7; the disease is acute kidney injury.